UNCY
Unicycive Therapeutics, Inc.
$7.94
+1.02%
2026-05-08
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Key Fundamentals
Forward P/E
1.14
EPS (TTM)
$-1.67
ROE
-141.1%
Profit Margin
0.0%
Debt/Equity
0.39
Price/Book
5.71
Beta
1.77
Market Cap
$208.0M
Avg Volume (10D)
568K
Recent Breakout Signals
No recent breakout signals detected for UNCY.
Recent Price Range (60 Days)
60D High
$8.34
60D Low
$5.98
Avg Volume
510K
Latest Close
$7.94
Get breakout alerts for UNCY
Sign up for Breakout Scanner to receive daily notifications when UNCY triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Unicycive Therapeutics, Inc. (UNCY) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors UNCY daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. UNCY operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.